Showing results (61-70 of 170) with videos related to

Sort By:
Pageof 17
The Australasian Journal of Dermatology|March 6, 2024
Paediatric indications and dosing guidance for advanced targeted treatments in AustraliaPatrick D Mahar, Susan J Robertson, David Orchard, et al.
The Journal of Dermatological Treatment|April 22, 2020
A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasisLynda Spelman, Diana Rubel, Alan Brnabic, et al.
The Australasian Journal of Dermatology|December 10, 2016
Australian dermatologists' perspective on skin of colour: Results of a national surveyMichelle A Rodrigues, Angelique L Ross, Steven Gilmore, et al.
Dermatologic Clinics|September 20, 2011
Evidence-based management of bullous pemphigoidBenjamin S Daniel, Luca Borradori, Russell P Hall, et al.
The Australasian Journal of Dermatology|February 22, 2023
A review of JAK and IL-23 inhibitors to treat vitiligoHenry Lee, Timothy L Cowan, Benjamin S Daniel, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 28, 2023
Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies: A Case ReportBabak Soleimani, Callum Board, Tony Yu, et al.
The Australasian Journal of Dermatology|July 11, 2022
Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE studyPeter Foley, Lynda Spelman, Dedee F Murrell, et al.
The Journal of Dermatological Treatment|May 11, 2017
Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis populationDiana Norris, Louise Photiou, Mark Tacey, et al.
BMC Infectious Diseases|January 9, 2020
Case report: meningitis as a presenting feature of anti-NMDA receptor encephalitisMaria Stavrou, Jing Ming Yeo, Alexander David Slater, et al.
International Journal of Dermatology|November 26, 2009
Long-term efalizumab therapy for patients with moderate-to-severe, chronic plaque psoriasis: results from an Australian expanded access programPeter Foley, Michael Freeman, Kurt Gebauer, et al.
Pageof 17